You are using an older browser version. Please use a supported version for the best MSN experience.

Biogen and Eisai report successful test on Alzheimer's treatment

CNBC's Shep Smith reports on positive news regarding a drug trial from Biogen and Japan's Eisai, which showed a 27% decrease in cognitive decline among early stage Alzheimer's patients.

UP NEXT

UP NEXT

More From CNBC

More From CNBC

image beaconimage beaconimage beacon